| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a40c39fa424236fb51b9fde9707ee78 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-624
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6829 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
| filingDate |
2008-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57d693f671f41cdc9f5f8eaa65765d93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d9580fd6cb12967980461499f943bee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a4a94ca88dfe6b2085c354947b85a1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_883e47f1ce274e1bf4f28a0fea5d907f |
| publicationDate |
2009-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009004734-A1 |
| titleOfInvention |
Mutated Anti-CD22 Antibodies With Increased Affinity To CD22-Expressing Leukemia Cells |
| abstract |
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11208632-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010210543-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9540438-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9238878-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10183998-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9879249-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11788066-B2 |
| priorityDate |
2001-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |